COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5adenoviral vector producing the SARS-CoV-2 spike protein. In this trial, the primarycomparison in terms of safety and immunogenicity will be between two different doselevels of COV2 booster vaccine (low, high), and two different administration methods(nasal drops, nasal spray). In addition, COV2 vaccine will also be evaluated in vaccinenaive subjects.
Not Provided
Biological: COVID-19 vaccine, low dose level
Test article
Other Name: COV2
Biological: COVID-19 vaccine, high dose level
Test article
Other Name: COV2
Other: Nasal Drops
Method of administration of test article
Other: Nasal Spray
Method of administration of test article
Inclusion Criteria
1. Has voluntarily signed the written informed consent
2. 18-75 years old
3. Good general health
4. a) Prior vaccination with at least two doses of any COVID-19 vaccine, OR b) No prior
COVID-19 vaccination
Exclusion Criteria
1. Pregnant, planning to become pregnant or breastfeeding women
2. COVID-19 infection within the last nine (9) months
3. Any other vaccination within the last two (2) months
Kuopio University Hospital
Kuopio, Northern Savonia, Finland
Investigator: Laura Jääskeläinen, RN
Contact: +358 40 7741104
laura.jaaskelainen@satucon.fi
Erkko Ylösmäki, PhD
+358 40 5836604
erkko.ylosmaki@rokote.com
Tobias Freitag, MD
tobias.freitag@rokote.com